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Objective: To identify microRNAs (miRNAs) differentially expressed at early stages of gestation (12e14
weeks) in the serum of pregnant women, who later developed severe preeclampsia (sPE) in the third
trimester of pregnancy (n ¼ 24) compared to women with normal pregnancy (n ¼ 24).
Materials and Methods: Sera from 12e14-week-gestation whole blood were subjected to microarray
analysis with TaqMan Low Density Array chips (human microRNA panel V3.0), and to quantitative real-
time polymerase chain reaction.
Results: By using the TaqMan Low Density Array chip technology, 19 mature miRNAs appeared differ-
entially expressed in the group of women who later developed sPE as compared to normal women. The
expression of four miRNAs (miR-1233, miR-520, miR-210, miR-144) was validated by quantitative real-
time polymerase chain reaction analysis. MiR-1233 was the most overexpressed in the serum of
women who later developed sPE.
Conclusion: CirculatingmiRNAs deserve further investigation in order to explore their potential role in the
pathogenesis of preeclampsia. In particular, miR-1233 might represent a potential marker of early sPE.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Preeclampsia (PE) affects approximately 4e5% of all pregnancies
worldwide [1]. It is a common pregnancy-related disease charac-
terized by hypertension and proteinuria, and a major cause of
maternal mortality, morbidity, perinatal death, preterm birth, and
intrauterine growth restriction [2]. Therefore, the identiﬁcation of
early biomarkers for PE is urgently needed. In this respect, in a
previous study by our group, we have investigated the role of the
TNF family member TRAIL, a pleiotropic cytokine showing
remarkable regulatory activities in the immune and cardiovascular
systems [3,4], as a potential marker of PE. Even though TRAIL is
expressed by placenta [5] and although its levels are modulated byd Child Health, IRCCS “Burlo
bstetrics & Gynecology. Publishedantiphospholipid antibodies [5], and are high in recurrent miscar-
riage [6], we did not ﬁnd any association between levels of circu-
lating TRAIL determined at 12e14 weeks of gestation and
subsequent development of PE [7].
Several studies have shown differential expression of given
microRNAs (miRNAs), which are a conserved group of ~22-nucle-
otide regulatory RNAs that play an important role in regulating
gene expression, in the human placentas of patients with PE
[8e13]. Interestingly, miRNAs speciﬁcally expressed in human
placentas were also detected in the sera of pregnant women and
found to be signiﬁcantly higher if compared to those of nonpreg-
nant women. Furthermore, their levels were reported to decrease
after delivery [13]. However, whether plasmatic miRNAs can
represent sensitive and early biomarkers for PE as proposed for
other pathologies [14], is currently unknown.
On these bases, we carried out a pilot study to evaluate the
potential usefulness of circulating miRNAs as early biomarkers of
severe PE (sPE). To this purpose, we have performed a microarray
analysis of circulating miRNAs at early gestational times (12e14by Elsevier Taiwan LLC. All rights reserved.
Table 1
Main characteristics of enrolled women: 24 preeclamptic and 24 controls, unless
speciﬁed.
Characteristics Preeclamptic
women
Controls p
Maternal age at delivery, y 34.4 (33.0e36.8) 33.7 (30.3e36.1) 0.216
Nulliparous 18 (75.0%) 15 (62.5%) 0.534
Prepregnancy BMI, kg/m2 22.4 (18.9e26.4) 23.0 (21.4e27.3) 0.288
BMI  30 kg/m2 2 (8.3%) 3 (12.5%) 1.000
Nonspontaneous conception 0 (0.0%) 2 (8.3%) 0.489
Not Caucasian 2 (8.3%) 1 (4.2%) 1.000
Smoking at 12th wk of gestation 2 (8.3%) 0 (0.0%) 1.000
Pregestational diabetes 0 (0.0%) 1 (4.2%) 1.000
Gestational diabetes 1 (4.2%) 0 (0.0%) 1.000
Birthweight below 10th centile
for gestational age
5 (20.8%) 0 (0.0%) 0.050
Percentile of birthweight for
gestational age
82.9 (41.5e94.1) 27.2 (11.1e37.3) 0.000
Gestational age at delivery 40.6 (39.3e41.1) 36.7 (35.1e39.0) 0.000
Induction of labor 9 (37.5%) 4 (16.7%) 0.193
Mode of delivery
Spontaneous vaginal 14 (58.3) 7 (29.2%) 0.080
Elective CD 2 (8.3%) 7 (29.2%) 0.137
Urgent CD 5 (20.8%) 10 (41.7%) 0.212
Operative vaginal 3 (12.5%) 0 (0.0%) 0.234
Live births 24 (100.0%) 24 (100.0%) 1.000
Umbilical pH < 7.1 0/18 (0.0%) 2/23 (8.7%) 0.495
Umbilical BE < 12 0/18 (0.0%) 3/22 (13.6%) 0.238
Apgar 1st minute < 5 0 (0.0%) 6 (25.0%) 0.022
Apgar 5th minute < 7 0 (0.0%) 2 (8.3%) 0.489
Fetal distress 7 (29.2%) 9 (37.5%) 0.760
Data in the table are frequencies and percentages or medians and interquartile
ranges. For dichotomous variables, p is from Fisher's exact two-tailed test; for
continuous variables, p is from ManneWhitney's rank-sum test.
BMI ¼ body mass index; CD ¼ cesarean delivery.
Table 2
Comparison of microarray and validation of some microRNAs (miRNAs) by quanti-
tative real time polymerase chain reaction. Quantiﬁcation values are reported in
parenthesis.
miRNAs Fold change >2 Chromosomal location
miR-1233 5.6 (5.4) 15
miR-650 3.7 22q11.22
miR-520a 3.5 (3.2) 19q13.42
miR-215 3.5 17q11.2
miR-210 3.3 (3.1) 17p13.1
miR-25 3.1 7q22.1
miR-518b 3.1 7q22.1
miR-193a-3p 2.6 17q11.2
miR-32 2.6 9q31.3
miR-204 2.5 9q21.12
miR-296-5p 2.4 Xp11.22
miR-152 2.4 17q21.32
miRNAs Fold change <0.5 Chromosomal location
miR-126 0.48 9q34.3
miR-335 0.42 7q32.2
miR-144 0.4 (0.39) 7q21-q22
miR-204 0.39 9q21.22
miR-668 0.33 14q32.31
miR-376a 0.32 14q32.31
miR-15b 0.24 3q25.33
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of pregnant women with normal pregnancies versus women who
developed sPE later in gestation.
Materials and methods
We have carried out a retrospective study to identify differen-
tially expressed miRNAs at early stages of gestation (12e14 weeks)
in the serum of pregnant women, who later developed sPE in the
third trimester of pregnancy. The procedures complied with the
Declaration of Helsinki and had been approved by the institutional
review board (Institute for Maternal and Child Health, IRCCS Burlo
Garofolo of Trieste). All participants signed a written informed
consent. Sera from whole blood of 12e14 weeks of gestation were
obtained and stored at 80C. For RNA isolation, pools of sera were
created by combining 40 mL of each sample, including 24 women
with normal pregnancies and 24 who developed sPE in the third
trimester of pregnancy. After the initial denaturizing step, we
routinely spiked in synthetic Caenorhabditis elegans miR-39 (cel-
miR-39) to a ﬁnal concentration of 104 pmol/ml for all samples in
order to control variations in RNA extraction and/or puriﬁcation
procedures because of the absence of homologous sequences in
humans. The pools were lysed with an equal volume of 2 Dena-
turing Solution (Ambion, Austin, TX, USA). RNA was isolated using
the mirVana PARIS kit, modiﬁed so that samples were extracted
twice with an equal volume of acid-phenol chloroform. RNA was
eluted with 100 mL of Ambion solution. We used TaqMan Low
Density Array (TLDA) chips (human microRNA panel V3.0; Applied
Biosystems Inc, Norwalk, CT, USA) to screen 754 unique speciﬁc
human miRNAs from the two pooled samples. A 300 ng sample of
human serum RNA from each pool was reverse transcribed using
the TaqMan miRNA RT Kit, and the TaqMan miRNA Multiplex RT
Assays, Human Pool Set. 250 ng of humanplasma RNAwas added to
each of the twomultiplex RT reactions (pool A and pool B Megaplex
RT-primers). Preampliﬁcation reactions were run according to the
manufacturer's protocol. A 75 mL aliquot of 0.1 TEwas added to the
PreAmp product, and 9 ml diluted PreAmp product was used to run
the real-time polymerase chain reaction (RT-PCR) reactions by
dispensing 100 ml of the PCR reaction mix into each port of the
TaqMan MicroRNA Array. The default PCR procedure was carried
out, and the analysis was performed using RQ manager software
(Applied Biosystems). DCT and DDCT were calculated using the
following mathematical formula: DCT ¼ CT sample  CT RNU6B,
DDCT ¼ DCT case  DCT control. Finally, the DDCT was normalized
against the cel-miR-39. Quantitative (q)RT-PCR was performed to
validate the 19 differentially expressed miRNAs identiﬁed in the
miRNAs microarray analysis. qRT-PCR was performed using uni-
versal Taq-man mix and miRNA-speciﬁc primers according to the
manufacturer's protocol. Reactions were run on an ABI Step 1 Plus
RT-PCR machine (Applied Biosystems) using the default cycling
conditions. All reactions were analyzed by using the 2DDCT calcu-
lation procedure. Normalization of experimental data was per-
formed using a spiked-in C. elegans control.
Results
The clinical characteristics of each individual patient and control
are summarized in Table 1. miRNAs microarray was performed on
48 serum samples obtained at 12e14 weeks of gestation, including
24 from women who developed sPE in the third trimester of
gestation and 24 from women with normal pregnancies. We
decided to pool the serum in order to bypass the high variability
present in individual samples. A total of 754 unique speciﬁc human
miRNAs were assayed. Bonferroni test correction to p value was
applied and only signiﬁcant miRNAs with p < 0.00007 wereselected. Nineteen differentially expressed miRNAs were identiﬁed
out of these, including 12 upregulated (miR-1233; miR-650; miR-
520a; miR-215; miR-210; miR-25; miR-518b; miR-193a-3p; miR-
32; miR-204; miR-296-5p; miR-152) and 7 downregulated (miR-
126; miR-335; miR-144; miR-204; miR-668; miR-376a; miR-15b) in
sPE, using TLDA chips (human microRNA panel V3.0). Four miRNAs
(miR-1233, miR-520a, miR-210, miR-144) were validated in sPE
serum sample by qRT-PCR. In particular, results summarized in
Table 2 show that circulating miR-1233 displayed the greater
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developed sPE in the third trimester of gestation and the group of
24 women with normal pregnancies.Discussion
Circulating miRNAs have emerged as potential novel diagnostic
biomarkers for different human pathologies such as cancer, tissue
injury, cardiovascular diseases, and also pathological pregnancy. In
this respect, although the mechanisms involved in the develop-
ment of PE remain poorly understood, our data have displayed
novel dysregulated miRNAs at early stages of gestation (12e14
weeks) in the serum of pregnant womanwho developed sPE in the
third trimester of pregnancy. In particular, we found 12 upregulated
and 7 downregulated miRNAs. Among the upregulatedmiRNAs, we
validated miR-210 [13] and miR-520a in sPE. With respect to our
current data, it is noteworthy that a previous study reported the
elevation of several miRNAs in the sera of women during early
gestation (i.e., within the 12th to 16th week of pregnancy) with later
onset of PE [14]. In our current study, we have identiﬁed miR-1233
through the TLDA chip technology and validated it by qRT-PCR, thus
highlighting it as the most over-expressed miRNA in sPE. Although
this is the ﬁrst report suggesting a potential role of miR-1233 in
predicting sPE, this miRNA has been already implicated in renal
carcinoma [15]. Interestingly, further miRNAs that were upregu-
lated in the serum of pregnant women who later developed sPE,
were related to cancer in previous studies: miR-650 to hepatocel-
lular carcinoma [16]; miR-32 andmiR-193a-3p to colon cancer [17];
miR-152 to endometrial cancer [18]; miR-215 and miR-204 in
metastatic renal cell carcinoma [19]. In addition, in line with our
current ﬁndings, miR-296-5p and miR-25 have been reported to be
elevated in placentas with sPE [20]. By contrast, several down-
regulated miRNAs in the serum of pregnant women who develop
sPE in late onset, have also been previously reported to be modu-
lated in cancer patients. In particular, miR-144 is correlated with
several types of cancers: its levels are signiﬁcantly decreased in
bladder cancer tissues [21] and in colorectal cancer [22], while miR-
126 [23] miR-335 [24], miR-668 [25], miR-15b [26], miR-204 [27]
are considered oncosuppressors. Taken together, our data suggest
a protumoral like signature of circulating miRNAs in women who
develop sPE at a later stage. Nevertheless, since the majority of
these miRNAs was not validated by qRT-PCR but it was only
analyzed by TLDA technology, conﬁrmatory studies with data
validation by qRT-PCR are needed to better explore the role of
miRNAs in PE pathogenesis.Conclusion
We have shown a potential link between early dysregulated
miRNAs expression and subsequent development of PE. We also
identiﬁed novel candidate miRNAs that may be relevant in the
pathogenesis of PE or as early disease's biomarkers. In particular,
miR-1233 showed the greatest differences between women who
developed sPE in the third trimester of pregnancy and womenwith
normal pregnancy, thus becoming a potential biomarker candidate.Conﬂicts of interest
The authors declare that they have no conﬂicts of interest.References
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